Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.60 |
| ▸ | HTR1D | P28221 | 2/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663279 | 1.00 | DPP4 (0.60) | DPP4HTR1DHTR1BDPP7DPP8 | |
| SCHEMBL8273672 | 0.85 | DPP4 (0.55) | DPP4DPP7 | |
| SCHEMBL14102394 | 0.85 | DPP4 (0.61) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL4665021 | 0.80 | DPP4 (0.72) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL6442733 | 0.79 | DPP4 (0.55) | DPP4SPHK2SPHK1 | |
| SCHEMBL6166949 | 0.79 | TRPV6 (0.51) | HTR1DHTR1BTRPV6 | |
| SCHEMBL8272572 | 0.76 | DPP4 (0.58) | DPP4DPP8DPP9 | |
| SCHEMBL8275926 | 0.75 | DPP4 (0.65) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL6445146 | 0.75 | DPP4 (0.69) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL4666705 | 0.75 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |